A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and simvastatin combination therapy to ABT-335 and simvastatin monotherapy in subjects with mixed dyslipidemia.

Trial Profile

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and simvastatin combination therapy to ABT-335 and simvastatin monotherapy in subjects with mixed dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2010

At a glance

  • Drugs Choline fenofibrate; Simvastatin
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2010 Results of the 52-week extension study have been presented at the 17th World Congress of Cardiology.
    • 01 Apr 2009 Patient numbers amended from 560 to 657 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top